KeynoteLung

Explore an Investigational Immunotherapy Trial for Lung Cancer

Our Keynote lung cancer clinical trials are studying pembrolizumab to see if it may help patients with lung cancer. Pembrolizumab is an investigational immunotherapy that targets the PD-1 pathway.

Pembrolizumab has been FDA-approved for use in certain types of cancer.

Keynote clinical trials are currently enrolling patients with non-small cell and small cell lung cancer. To see if your patients qualify for one of these trials, contact our clinical trial information center at 1-888-577-8839. If you are interested in partnering with us as an investigator, call 1-800-290-4339.

15

Active Trials

5

Trials Recruiting

105

US Trial Locations

Explore Active Clinical Trials

Trial Description Keynote Trial Condition Phase Status
keynote study logo Study of Pembrolizumab vs Placebo for Participants With Non-small Cell Lung Cancer After Resection With or Without Standard Adjuvant Therapy 091 Non-small Cell Lung Cancer Phase 3 Recruiting
keynote study logo A Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab in Adults With First Line Metastatic Squamous Non-small Cell Lung Cancer 407 Non-small Cell Lung Cancer Phase 3 Active, not recruiting
keynote study logo Study of Pembrolizumab Given With Ipilimumab or Placebo in Participants With Untreated Metastatic Non-small Cell Lung Cancer 598 Carcinoma, Non-Small-Cell Lung Phase 3 Recruiting
keynote study logo Efficacy and Safety of Pembrolizumab With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage IIB or IIIA Non-small Cell Lung Cancer 671 Non-small Cell Lung Cancer Phase 3 Recruiting
keynote study logo Study of Pemetrexed + Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With Tyrosine Kinase Inhibitor- (TKI) -Resistant Epidermal Growth Factor Receptor- (EGFR)-Mutated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) 789 Non-small Cell Lung Cancer Phase 3 Recruiting
keynote study logo Study of Pembrolizumab in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma 001 Cancer, Solid Tumor Phase 1 Active, not recruiting
keynote study logo Study of Two Doses of Pembrolizumab Versus Docetaxel in Previously Treated Participants With Non-Small Cell Lung Cancer 010 Non Small Cell Lung Cancer (NSCLC) Phase 2/Phase 3 Active, not recruiting
keynote study logo Study of Pembrolizumab Monotherapy in Advanced Solid Tumors and Pembrolizumab Combination Therapy in Advanced Non-small Cell Lung Cancer/ Extensive-disease Small Cell Lung Cancer 011
  • Solid Tumor
  • Non-small Cell Lung Cancer
  • Small Cell Lung Cancer
Phase 1 Active, not recruiting
keynote study logo A Study of Pembrolizumab in Combination With Chemotherapy or Immunotherapy in Participants With Non-small Cell Lung Cancer 021 Non-small Cell Lung Carcinoma Phase 1/Phase 2 Active, not recruiting
keynote study logo Study of Pembrolizumab Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer 024 Non-Small Cell Lung Carcinoma Phase 3 Active, not recruiting
keynote study logo Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of Pembrolizumab in Chinese Participants With Non-Small-Cell Lung Cancer 032 Non-Small-Cell Lung Cancer Phase 1 Active, not recruiting
keynote study logo Study of MK-3475 Versus Platinum-based Chemotherapy for Participants With PD-L1-positive Advanced or Metastatic Non-small Cell Lung Cancer 042 Non-small Cell Lung Cancer Phase 3 Active, not recruiting
keynote study logo Study of Platinum+Pemetrexed Chemotherapy With or Without Pembrolizumab in Participants With First Line Metastatic Non-squamous Non-small Cell Lung Cancer 189 Non-Small-Cell Lung Carcinoma Phase 3 Active, not recruiting
keynote study logo A Study of Pembrolizumab in Combination With Etoposide/Platinum for Participants With Extensive Stage Small Cell Lung Cancer 604
  • Small Cell Lung Cancer
  • SCLC
Phase 3 Active, not recruiting
keynote study logo A Trial of Pembrolizumab in Combination With Chemotherapy and Radiotherapy in Stage III NSCLC. 799 Non-small Cell Lung Cancer Phase 2 Recruiting
keynote study logo Study of Pembrolizumab in Participants With Advanced Non-small Cell Lung Cancer 025 Non-small Cell Lung Cancer Phase 1 Completed